Premium
Serum binding of nifedipine and verapamil in patients with ischaemic heart disease on monotherapy.
Author(s) -
Rumiantsev DO,
Piotrovskii VK,
Metelitsa VI,
Slastnikova ID,
Martsevich Yu S.,
Kokurina EV
Publication year - 1989
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1989.tb05438.x
Subject(s) - verapamil , nifedipine , dosing , pharmacology , medicine , ischaemic heart disease , drug interaction , pharmacokinetics , in vitro , oral administration , chemistry , calcium , biochemistry
Serum free fractions of nifedipine, verapamil and some of their metabolites were measured in patients with ischaemic heart disease receiving single oral dose and chronic monotherapy and were compared with those obtained in vitro. The percentages of unbound nifedipine and verapamil in vitro (concentration range 50‐200 and 150‐400 ng ml‐1, respectively) were 2.51 and 7.23%, respectively, and did not differ from those found on monotherapy with these drugs (2.05 and 8.08%, respectively), and after single dosing. It is suggested that, during treatment with nifedipine or verapamil, their serum metabolites do not affect binding of the parent drugs to serum proteins.